A randomized, placebo-controlled study published in the Journal of Asthma (2010; 47(1):83–92) examined magnesium supplementation in adults with mild to moderate asthma. The study included 55 participants between the ages of 21 and 55, who were randomly assigned to receive either 340 mg of magnesium per day or placebo for approximately six and a half months.
Asthma severity and control were assessed using pulmonary function testing, methacholine challenge testing, and standardized questionnaires evaluating symptom severity and quality of life. Participants receiving magnesium supplementation demonstrated greater resistance to methacholine-induced bronchoconstriction and showed improvements in pulmonary function measures compared with the placebo group. Higher scores were also reported in quality-of-life assessments among those receiving magnesium.
